Floating IPN GHB Formulation with Gas-Generating Agent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gastroretentive drug delivery systems, particularly those using floating rafts, lack flexibility in tailoring properties to achieve desired attributes of floating, swelling, integrity, and sustained drug release, limiting their practical applications due to dependence on the properties of the polymers used, and existing formulations of gamma-hydroxybutyrate (GHB) face challenges such as high sodium levels and immediate release issues.
Innovation Solution
An orally administrable extended release composition comprising a floating interpenetrating polymer network (IPN) forming system with a non-toxic gas generating agent and an IPN forming polymer blend, which self-assembles in situ to form a floating IPN that controls the release of GHB, using anionic polymers and galactomannan polysaccharides that cross-link ionically with a cross-linking agent to form a network that entraps the drug and gas, providing prolonged gastric residence and release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional floating raft systems are used for gastroretentive drug delivery, then gastric retention is achieved, but flexibility in tailoring properties for desired floating, swelling, integrity, and sustained drug release is limited
Solution Approach 1:
The patent employs interpenetrating polymer networks (IPNs) composed of multiple polymer systems (e.g., alginate-guar gum IPN, chitosan-gelatin IPN) that combine different polymer properties within a single matrix. This composite structure enables simultaneous achievement of gastric retention, controlled swelling, structural integrity, and sustained drug release by leveraging the complementary characteristics of each polymer component.
Solution Approach 2:
The patent utilizes pH-dependent crosslinking mechanisms where the IPN structure transforms from linear to crosslinked conformation in response to gastric pH changes. This parameter change enables the system to maintain flexibility during formulation while achieving desired structural properties and drug release characteristics in the gastric environment.
2Quantity of substance
If GHB is formulated with high sodium levels to achieve therapeutic effect, then drug potency is improved, but side effects increase
Solution Approach 1:
The patent changes the ionic composition parameter of the GHB formulation by using calcium carbonate instead of sodium salts. This parameter change maintains the therapeutic effectiveness of GHB while eliminating the harmful high sodium content, as calcium carbonate provides the necessary counterion without the adverse cardiovascular effects associated with sodium.
Solution Approach 2:
The patent converts the typically harmful high sodium content into a benefit by using calcium carbonate, which not only provides the necessary counterion for GHB but also offers additional advantages such as antacid properties and reduced cardiovascular side effects, thereby transforming a potential harm (high ionic content) into a beneficial formulation characteristic.
3Speed
If GHB is formulated for immediate release to achieve rapid therapeutic effect, then onset of action is improved, but controlled release and sustained therapeutic effect are compromised
Solution Approach 1:
The patent incorporates a gas-generating system (sodium bicarbonate and citric acid) that activates preliminary upon contact with gastric fluid. This preliminary action creates bubbles that facilitate rapid dispersion and absorption of GHB for immediate therapeutic effect, while the IPN matrix simultaneously provides sustained release through its crosslinked structure.
Solution Approach 2:
The patent merges two opposing release mechanisms into a single formulation: the gas-generating system provides immediate release through rapid dispersion, while the IPN matrix provides sustained release through controlled diffusion. This combination enables both rapid onset of action and prolonged therapeutic effect within the same dosage form.
4Adaptability or versatility
If IPN forming blend self-assembles in situ to form floating IPN, then flexibility and control over drug release is improved, but device complexity increases
Solution Approach 1:
The patent employs a self-assembling IPN forming blend that automatically forms the crosslinked network structure upon contact with gastric fluid, without requiring external intervention or complex manufacturing processes. The polymers and crosslinking agents self-organize into the desired IPN structure, simplifying manufacturing while maintaining control over drug release properties.
Solution Approach 2:
The patent uses calcium carbonate as an intermediary substance that facilitates the crosslinking process. Calcium carbonate serves as both a counterion for GHB and a crosslinking agent for the polymer chains, enabling the self-assembly process while maintaining formulation simplicity. This intermediary role reduces the need for complex external crosslinking mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The floating IPN composition effectively prolongs the retention of GHB in the upper gastrointestinal tract, achieving a controlled and sustained release of the drug, improving bioavailability and patient compliance by reducing side effects associated with high sodium levels and immediate release.
Implementation Method 1
using anionic polymers and galactomannan polysaccharides that cross-link ionically with a cross-linking agent to form a network
Implementation Method 2
floating IPN forming system comprising at least one non-toxic gas generating agent
Data Source
AI summary
GHB drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least GHB drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the GHB drug entrapped therein for at least about 3 hours.